MXCT MEXC RealStocks
Own real MXCT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:26:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
MaxCyte, Inc. (MXCT) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $1.26, with a market capitalization of $120.80M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.64 to $1.81. This page covers its latest market performance, valuation, price trends and company information.
$120.80M | |
$1.16 | |
$1.26 | |
$1.15 | |
$1.17 | |
858.49K | |
1.02M | |
-- | |
$1.81 | |
$0.64 | |
-- | |
2026-06-30 |
MaxCyte, Inc. (MXCT) last closed at $1.26 as of 2026-11-19 00:33:00, up 10.26% ($0.12) from the previous close of $1.17.
During the latest regular trading session, MXCT traded between $1.15 and $1.26, with a volume of 858.49K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, MaxCyte, Inc. (MXCT) moved from $1.13 to $1.26, representing a gain of 11.15% ($0.13).
The stock traded between $1.02 and $1.42 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 2.02 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 52.7%
MXCT is currently trading at $1.26, placing it 52.7% of the way from its 52-week low of $0.64 to its 52-week high of $1.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 91 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MaxCyte, Inc. (MXCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MXCT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MXCT shares and USD.
MXCT Shares to USD
1.00 MXCT shares = 1.256 USD
Calculations are estimates based on the latest available price and are for reference only.